World Health Organisation ends hydroxycholorquine trial for COVID-19, citing 'little or no benefit'
The World Health Organisation says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalised with COVID-19.
WHO said today it has "accepted the recommendation" from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS.
Hydroxychloroquine is a commonly used drug to treat malaria, but has been dubiously linked to curing coronavirus. AP
The drugs were being compared with standard care for hospitalised patients.
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir "produce little or no reduction in the mortality of hospitalised COVID-19 patients when compared to standard of care".
The agency adds that while there was no "solid evidence" of increased mortality for hospitalised patients given the drugs, there were "some associated safety signals in the clinical laboratory findings" of an associated trial.
Hydroxychloroquine is a common preventative medication for malaria, though it has significant side effects. AP
WHO says the decision won't affect possible trials on patients who aren't hospitalised, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.
Share a tip-off, video or photo with us
